SAGE Therapeutics Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
598
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$795M
- Investors
-
1
SAGE Therapeutics General Information
Description
Developer of brain health medicines designed to treat central nervous system disorders. The company's technology offers positive allosteric modulators, GABA receptor targeting, NMDA receptor targeting, once-daily oral dosing, rapid-acting antidepressant effects, and intravenous injection formulations, enabling patients to access therapies for postpartum depression, major depressive disorder, and other neuropsychiatric conditions.
Contact Information
Website
www.sagerx.comCorporate Office
- 55 Cambridge Parkway
- Cambridge, MA 02142
- United States
Corporate Office
- 55 Cambridge Parkway
- Cambridge, MA 02142
- United States
SAGE Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 17. Merger/Acquisition | 31-Jul-2025 | $795M | Completed | Generating Revenue | ||
| 16. Merger/Acquisition | 27-Jan-2025 | Cancelled | Generating Revenue | |||
| 15. PIPE | 19-Oct-2024 | Completed | Generating Revenue | |||
| 14. PIPE | 31-Dec-2020 | Completed | Generating Revenue | |||
| 13. Secondary Transaction - Open Market | 31-Mar-2018 | Completed | Generating Revenue | |||
| 12. 2PO | 20-Sep-2017 | Completed | Generating Revenue | |||
| 11. Secondary Transaction - Open Market | 31-Mar-2017 | Completed | Generating Revenue | |||
| 10. PIPE | 08-Sep-2016 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Open Market | 31-Mar-2016 | $292M | Completed | Generating Revenue | ||
| 8. 2PO | 14-Apr-2015 | $120M | $292M | Completed | Generating Revenue |
SAGE Therapeutics Comparisons
Industry
Financing
Details
SAGE Therapeutics Competitors (32)
One of SAGE Therapeutics’s 32 competitors is Intracellular Therapies, a Formerly VC-backed company based in Bedminster, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intracellular Therapies | Formerly VC-backed | Bedminster, NJ | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Marinus Pharmaceuticals | Private Equity-Backed | Radnor, PA | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Merck & Co. | Corporation | Rahway, NJ |
SAGE Therapeutics Signals
SAGE Therapeutics Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| BB Biotech | Asset Manager | Minority | ||
| Biogen | Corporation | Minority | ||
| EcoR1 Capital | Venture Capital | Minority | ||
| Foresite Capital | Growth/Expansion | Minority |
SAGE Therapeutics Investments (1)
SAGE Therapeutics’s most recent deal was a PIPE with Ligand Pharmaceuticals for . The deal was made on 14-May-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals | 14-May-2014 | PIPE | Drug Discovery |
SAGE Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
27.71 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
SAGE Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sage Securities Corporation | Cambridge, MA | 2019 |
SAGE Therapeutics FAQs
-
When was SAGE Therapeutics founded?
SAGE Therapeutics was founded in 2010.
-
Where is SAGE Therapeutics headquartered?
SAGE Therapeutics is headquartered in Cambridge, MA.
-
What is the size of SAGE Therapeutics?
SAGE Therapeutics has 598 total employees.
-
What industry is SAGE Therapeutics in?
SAGE Therapeutics’s primary industry is Drug Discovery.
-
Is SAGE Therapeutics a private or public company?
SAGE Therapeutics is a Private company.
-
What is the current valuation of SAGE Therapeutics?
The current valuation of SAGE Therapeutics is .
-
What is SAGE Therapeutics’s current revenue?
The current revenue for SAGE Therapeutics is .
-
How much funding has SAGE Therapeutics raised over time?
SAGE Therapeutics has raised $1.15B.
-
Who are SAGE Therapeutics’s investors?
ARCH Venture Partners, BB Biotech, Biogen, EcoR1 Capital, and Foresite Capital are 5 of 8 investors who have invested in SAGE Therapeutics.
-
Who are SAGE Therapeutics’s competitors?
Intracellular Therapies, ACADIA Pharmaceuticals, Marinus Pharmaceuticals, Vertex Pharmaceuticals, and Merck & Co. are some of the 32 competitors of SAGE Therapeutics.
-
When was SAGE Therapeutics acquired?
SAGE Therapeutics was acquired on 31-Jul-2025.
-
Who acquired SAGE Therapeutics?
SAGE Therapeutics was acquired by Supernus.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process